温州市生物医药协同创新中心
科研队伍
学术带头人
您现在的位置:首页 >> 科研队伍 >> 学术带头人


李校堃 5.jpg

李校堃,教授,教育部“长江学者”


李校堃,教授,博士生导师,教育部“长江学者”特聘教授。基因工程药物国家工程研究中心首席科学家,教育部生物反应器与药物科学开发工程研究中心首席科学家,国家“万人计划”教学名师,“教育部新世纪优秀人才”,“新世纪百千万人才工程”国家级人选,卫生部突出贡献中青年专家、全国优秀科技工作者,享受国务院政府特殊津贴。中国医药生物技术协会副理事长,中国生物工程学会常务理事,中国医药质量管理协会副会长,国际华人生长因子学会常务理事长,中国生物工程学会转化医学分会主任委员,中华医学会创伤学分会创伤药物与转化应用委员会主任委员。20余年一直致力于以成纤维细胞生长因子(FGFs)为代表的生物药物的基础与应用研究。获国家授权发明专利30项,其中5项已实现产业化,累计产值超过15亿元。围绕相关基因工程药物开发应用及技术体系创新,先后获得获得国家科技进步一等奖、国家技术发明二等奖、国家科技进步二等奖等国家级奖项,以及中华医学科技一等奖、中国药学会科学技术一等奖、浙江省科技进步一等奖、教育部成果奖励一等奖、中国专利优秀奖等省部级一等奖8项。在国际知名的基础医学与转化医学研究相关领域的Cell Metab(IF=17.56)、Molecular Cell(IF=15.28)、Circulation (IF=14.43)、J Hepatology(IF=11.33)、Trends Pharmacol Sci(IF=11.53)、PNAS(IF=9.67)、Biomaterials(IF=8.56)、Diabetes(IF=8.14)等杂志发表SCI论文236篇,其中一区论文14篇,是我国基因工程药物研究开发和成果转化的代表人物。


Prof. Xiaokun Li, Cheung Kong Scholar in 2008 by the Ministry of Education and the "National Distinguished Teacher" in 2012. He also received the award of "Young and Middle-Aged Experts with Outstanding Contributionfrom the Ministry of Public Health in 2012.

He is a pioneer in engineering protein drugs in China, and has made exceptional contributions to the development and innovation of FGF-based biologics from basic biochemical research and protein engineering to their industrialization and clinical applications. He has successfully developed three new Class A drugs (rbbFGF, rhbFGF, rhaFGF under the Chinese commercial names of 贝复济®、盖扶®、艾夫吉夫®, respectively) with full intellectual property rights for the treatment of severe trauma and refractory ulcers. The rbbFGF also represents the first FGF recombinant protein drug in the world. These drugs have received wide application in the clinics with improved patient therapeutic outcome.

In a continued effort to thoroughly understand the biological mechanism of FGFs and explore novel clinical applications, Prof. Li and his FGF research team have recently uncovered the close link of FGF21 to human type 2 diabetes, and discovered a novel mechanism underlying FGF21 regulation of glucose and lipid metabolism via the FGFR21/PPARγ/adiponectin signaling axis (Cell Metab. 2013). His group further demonstrated that FGF21-mediated signaling also participates in the development and progression of atherosclerosis (Circulation 2015), a highly significant finding highlighted by Nature Reviews and was considered by Cell Metab (2015) as one of the Top-10 groundbreaking discoveries. These findings together provide a secure scientific basis for the potential application of FGF21 in the treatment of type 2 diabetes. Dr. Lis team has completed all the preclinical testing for FGF21, and the related technology has been transferred to Biotechnology Co., Ltd in 2015. Recently, they proposed one theory that one FGFR monomer recruits PLCγ delivering it for phosphorylation by the other FGFR (Mol cell 2015), and it regarded as pioneering discovery in the domain of receptor kinase.

For his outstanding contributions to the basic and translational research on FGF-based biologics, Prof. Li has received four national awards including the Second Prize of National Technological Innovation Award (2009), the First Prize and Second Prize of National Scientific and Technological Progress Award (2015, 2002), the Third Prize of National Scientific and Technological Progress Award (1999), as well as 4 provincial first prizes including Chinese Medical Association Award and Chinese Pharmaceutical Association Award.